$0.818700
-0.0095-1.15%
At Close: -
$0.833300
0.011.78%
After Hours: Jul 5, 6:01 PM EDT
15 minutes delayed
Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
05/08/2024 | KPTI | Karyopharm Therapeutics | FY | 2024 | — | — | — | $140.00M | $160.00M | $146.52M | Get Alert |
02/29/2024 | KPTI | Karyopharm Therapeutics | FY | 2024 | — | — | — | $140.00M | $160.00M | $152.02M | Get Alert |
01/08/2024 | KPTI | Karyopharm Therapeutics | Q4 | 2023 | — | — | — | $33.60M | $33.60M | $37.64M | Get Alert |
01/08/2024 | KPTI | Karyopharm Therapeutics | FY | 2023 | — | — | — | $146.00M | $146.00M | $150.03M | Get Alert |
11/02/2023 | KPTI | Karyopharm Therapeutics | FY | 2023 | — | — | — | $145.00M | $160.00M | $151.17M | Get Alert |
08/02/2023 | KPTI | Karyopharm Therapeutics | FY | 2023 | — | — | — | $145.00M | $160.00M | $150.34M | Get Alert |
05/04/2023 | KPTI | Karyopharm Therapeutics | FY | 2023 | — | — | — | $145.00M | $160.00M | $157.37M | Get Alert |
02/15/2023 | KPTI | Karyopharm Therapeutics | FY | 2023 | — | — | — | $160.00M | $175.00M | $163.24M | Get Alert |
01/09/2023 | KPTI | Karyopharm Therapeutics | Q4 | 2022 | — | — | — | $34.20M | $34.20M | $38.13M | Get Alert |
01/09/2023 | KPTI | Karyopharm Therapeutics | FY | 2022 | — | — | — | $157.70M | $157.70M | $161.68M | Get Alert |
11/03/2022 | KPTI | Karyopharm Therapeutics | FY | 2022 | — | — | — | $155.00M | $165.00M | $157.23M | Get Alert |
08/04/2022 | KPTI | Karyopharm Therapeutics | FY | 2022 | — | — | — | $155.00M | $165.00M | $160.03M | Get Alert |
01/11/2021 | KPTI | Karyopharm Therapeutics | FY | 2020 | — | — | — | $108.00M | $109.00M | $98.14M | Get Alert |
01/11/2021 | KPTI | Karyopharm Therapeutics | Q4 | 2020 | — | — | — | $35.00M | $36.00M | $24.91M | Get Alert |
There have been no specific sales or earnings guidance reported for Karyopharm Therapeutics in recent months.
Browse guidance and forecast on all stocks.